Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Hutchmed: Clinical Trials & FDA Approval Profile

Hutchmed (Global / Institutional) sponsors 22 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 11 active protocols (8 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)13.6%
Median Closed Enrollment vs National (145 pts)70 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Hutchmed
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)22
Active Pipeline (Recruiting Now)11 (8)
Completed vs Stopped Early8 / 3 (13.6%)
Median Closed Actual Enrollment70 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Hutchmed
Hospital Research SiteLocationShared Protocols
Henan Cancer HospitalZhengzhou, Henan9
Hunan Cancer HospitalChangsha, Hunan8
Ruijin Hospital, Shanghai Jiaotong University School of MedicineShanghai, Shanghai Municipality7

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Hutchmed
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06387069A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaPhase IIIRECRUITING
NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLPhase IIIRECRUITING
NCT06361888A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in MetasPhase II/IIIRECRUITING
NCT06584032Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial CancerPhase IIIRECRUITING
NCT05535933HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaPhase II/IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Hutchmed Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI